Inhibition of NF-kappaB activation

Abstract

A H. pylori thioredoxin protein having a seq ID No. 1 is capable of inhibiting the activation of NF-κB. The protein may be used in treating inflammation.

1 . A  H. pylori  protein or derivative or fragment or mutant or variant thereof capable of inhibiting the activation of NF-κB.  
     
     
         2 . A  H. pylori  protein as claimed in  claim 1  wherein the protein is a thioredoxin or derivative or fragment or mutant or variant thereof.  
     
     
         3 . A  H. pylori  protein as claimed in  claim 1  wherein the protein has the following amino acid sequence:  
       
         
           
                 
                 
                 
                 
                 
               
                     
                 
                   MSHYIELTEE 
                   NFESTIKKGV 
                   ALVDFWAPWC 
                   GPCKMLSPVI 
                     
                 
                     
                 
                   DELASEYEGK 
                   AKICKVNTDE 
                   QEELSAKFGI 
                   RSIPTLLFTK 
                 
                     
                 
                   DGEVVHQLVG 
                   VQTKVALKEQ 
                   LNKLLG 
                 
                     
                 
             
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         4 . A thioredoxin or derivative or fragment or mutant or variant thereof containing the redox active peptide sequence CGPC.  
     
     
         5 . Prokaryotic or eukaryotic thioredoxins having potent immune-suppressive effects.  
     
     
         6 . Polypeptides containing the redox active peptide sequence CGPC.  
     
     
         7 . A  H. pylori  protein having the following amino acid sequence:  
       
         
           
                 
                 
                 
                 
                 
               
                     
                 
                   MSHYIELTEE 
                   NFESTIKKGV 
                   ALVDFWAPWC 
                   GPCKMLSPVI 
                     
                 
                     
                 
                   DELASEYEGK 
                   AKICKVNTDE 
                   QEELSAKFGI 
                   RSIPTLLFTK 
                 
                     
                 
                   DGEVVHQLVG 
                   VQTKVALKEQ 
                   LNKLLG 
                 
                     
                 
             
                
                
                
                
                
                
                
               
            
           
         
       
     
     
         8 . A derivative or fragment or mutant or variant of the protein of  claim 7 .  
     
     
         9 . Use of a  H. pylori  thioredoxin protein or derivative or fragment or variant thereof as claimed in  claim 1  in the prevention and/or treatment of inflammation.  
     
     
         10 . Use of a  H. pylori  thioredoxin protein or derivative or fragment or variant thereof as claimed in  claim 9  in the prevention and/or treatment of inflammatory bowel disease.  
     
     
         11 . Use of a  H. pylori  thioredoxin protein or derivative or fragment or variant thereof as claimed in  claim 9  in the prevention and/or treatment of rheumatoid/autoimmune arthritis.  
     
     
         12 . Use of a  H. pylori  thioredoxin protein or derivative or fragment or variant thereof as claimed in  claim 9  in the prevention and/or treatment of any chronic disease wherein NF-κB is transcriptionally activated.  
     
     
         13 . Use as claimed in  claim 11  for the prevention and/or treatment of any one or more of autoimmune arthritis or other autoimmune diseases, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis or autoimmune encephalomyelitis.  
     
     
         14 . Use of a  H. pylori  thioredoxin protein or derivative or fragment or mutant or variant thereof as claimed in any preceding claim in soft tissue injury.  
     
     
         15 . A  H. pylori  thioredoxin protein or derivative or fragment or mutant or variant thereof as claimed in  claim 1  for use in the preparation of a medicament for the treatment and/or prophylaxis of any chronic disease wherein NF-κB is transcriptionally activated.  
     
     
         16 . A protein as claimed in  claim 1  for use in the preparation of a medicament for the treatment and/or prophylaxis of any chronic disease wherein NF-K B is transcriptionally activated.